GEORGE GABRIEL TOLDNESS: Open Payments
NPI 1720646045 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$795 in 32 payments from 9 companies in 2025. Trend: 2023 $602 · 2024 $629 · 2025 $795
Food & beverage: $795
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $272 |
| GlaxoSmithKline, LLC. | 9 | $207 |
| Amgen Inc. | 4 | $90 |
| PFIZER INC. | 3 | $71 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Novo Nordisk Inc | 2 | $36 |
| ABBVIE INC. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
Products named: TRELEGY ELLIPTA, FARXIGA, OTEZLA, CAPLYTA, AIRSUPRA, ELIQUIS, Rybelsus, PAXLOVID.
Industry payments across NV — which companies pay providers there.
